Weight-loss drug developer Metsera reveals wider loss in US IPO filing

(Reuters) – Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a U.S. initial public offering on Friday. The terms of the…